COX enzymes have been investigated thoroughly as targets for HNSCC prevention and treatment, using non-steroidal anti-inflammatory drugs (NSAIDs) alone, or in combination with other targeted therapies, including EGFR inhibitors [9,10,11]. Here, EGFR is linked to head and neck squamous cell carcinoma.